Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: Effect of proliferative heterogeneity and radiation cross-fire

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 385-390

  Neshasteh Riz, A ^a,b   Mairs, R J ^b   Angerson, W J ^b   Stanton, P D ^b   Reeves, J R ^b   Rampling, R ^b   Owens, J ^c   Wheldon, T E ^a,b  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Bystander effect; Cross fire irradiation; Glioma; Iododeoxyuridine; Proliferation; Spheroids

Indexed keywords

IDOXURIDINE; IODINE 123; IODINE 125; IODINE 131; RADIOPHARMACEUTICAL AGENT; DNA; RADIOACTIVE IODINE;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CELL CYCLE S PHASE; CELL KILLING; CELL PROLIFERATION; CLONOGENESIS; CYTOTOXICITY; GLIOMA CELL; GROWTH CURVE; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; RADIATION; RADIOIODINATION; SPHEROID CELL; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; GLIOMA; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; RADIATION EXPOSURE;

CELL DIVISION; DNA; GLIOMA; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 0031594612     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.61     Document Type: Article

References (31)

1. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumour model. Int J Radiat Oncol Biol Phys 21: 1541-1551
2. Baranowska-Kortylewicz J, Helseth LD, Lai J, Schneiderman MH, Schneiderman GS and Dalrymple GV (1994) Radiolabelling kit generator for 5-radiohalogenated uridines. J Labelled Comp Radiopharmaceut 34: 513-521
3. 8HTdR. Radiat Res 67: 332-343
4. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N and Larson M (1996) Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metatastic to liver. J Nucl Med 37 (suppl.): 29S-32S
5. Freshney RI, Sherry A, Hassanzadeh M, Freshney M and Crilly P (1980) Control of cell proliferation in human glioma by glucocorticoids. Br J Cancer 41: 857-866
6. Hofer KG and Hugues WL (1971) Radiotoxicity of intranuclear tritium, iodine-125 and iodine-131. Radiat Res 47: 94-109
7. 3H nuclear versus cytoplasmic radiation effects in murine L1210 leukamia. Int J Radiat Biol 28: 225-241
8. Humm JL (1986) Dosimetric aspects of radiolabelled antibodies for tumour therapy. J Nucl Med 27: 1490-1496
9. Kassis AI (1994) Toxicity and therapeutic effects of low-energy electrons. Nucl Instrum Meth Phys Res (B) 87: 279-284
10. Kassis AI and Adelstein SJ (1996) Preclinical animal studies with radiolabelled IUdR. J Nucl Med 37: 343-352
11. 125I in mammalian cells. Radiat Res 111: 305-318
12. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 109: 78-89
13. 125I]iodo-2′-deoxyuridine in rat brain tumours: diagnostic and therapeutic implications in humans. Cancer Res 50: 5199-5203
14. 124I]iodo-2′-deoxyuridine in a patient with a brain tumour. J Nucl Med 37 (suppl.): 19S-22S
15. Kwok TT and Twentyman PR (1987) The use of a tritiated thymidine suicide technique in the study of the cytotoxic drug response of cells located at different depths within multicellular spheroids. Br J Cancer 55: 367-374
16. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R and Berns A (1991) Simplified mammalian DNA isolation procedure. Nucleic Acid Res 19: 4293
17. 125I]iodo-2′-deoxyuridine in the treatment of colorectal metastatic to the liver. J Nucl Med 37 (suppl.): 25S-29S
18. Makrigiorgos GM, Kassis AI, Baranowska-Kartylewicz J, Mcelvany KD, Welch MJ, Sastry KSR and Adelstein SJ (1989) Radiotoxicity of 5-[I-123]iodo-2′-deoxyuridine in V79 cells. A comparison with 5-[I-125]iodo-2′-deoxyuridine. Radiat Res 118: 532-544
19. Martin RF and Haseltine WA (1981) Range of radiochemical damage to DNA with decay of iodine-125. Science 213: 896-898
20. 125I]iodo-2′-deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med 37 (suppl.): 16S-19S
21. 125I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 37 (suppl.): 22S-25S.
22. Neshasteh-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R and Mairs RJ (1997) Incorporation of iododeoxiuridine in multicellular spheroids: implications for DNA-largeted radiotherapy using Auger electron emitter. Br J Cancer 75: 493-499
23. O'Donoghue JA, Bardies M and Wheldon TE (1995) Relationships between tumour size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36: 1902-1909
24. Raaphorst GP, Feeley MMDa, Silva VfDanjoux CE and Gerig LH (1989) A comparison of heat and radiation sensitivity of three human glioma cell lines. In J Radiat Oncol Biol Phys 17: 615-622
25. Rodriguez R, Ritter M, Fowler JF and Kinsella TJ (1994) Kinetics of cell labelling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 29: 105-113
26. Schneiderman MH and Schneiderman GS (1996) Radioiododeoxyuridine in cancer therapy: an in vitro approach to developing in vivo strategies. J Nucl Med 37 (suppl.): 6S-9S
27. Schwartz JL, Mustafi R, Hughes A and Desomber ER (1996) DNA and chromosome breaks by iodine-123 labelled estrogen in Chinese-hamster ovary cells. Radiat Res 146: 151-158
28. Sutherland RM (1988) Cell environment interactions in tumour microregions - the multicell spheroid model. Science 240: 177-184
29. Taghian A, Suit H, Phil D, Pardo F, Gioioso D, Tomkinson K, DuBois W and Gerweck L (1992) In vitro intrinsic radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 23: 55-62
30. 211At]astato-2′-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res 56: 1204-1209
31. Wheldon TE and O'Donoghue JA (1990) The radiobiology of targeted radiotherapy. Int J Radiat Biol 58: 1-21